Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3Unknown 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × genexol-PM × Clear all
NCT02263495 2020-07-14

EG_PG

Asan Medical Center

Phase 2 Completed
118 enrolled
Breast

Breast Neoplasms

NCT00876486 2017-05-01

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Samyang Biopharmaceuticals Corporation

Phase 3 Completed
213 enrolled
Breast

Breast Neoplasms

NCT02064829 2016-03-25

TRIBECA

Sorrento Therapeutics, Inc.

Phase NA Completed
111 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡